Astroenica, the largest pharmaceutical manufacturer in the United Kingdom, is committing to offer Americans major discounts on their vast catalog of prescription drugs. One of the great companies, by the way, and a most favored nation's pricing clause. So, most favored nation is uh you're going to pay whatever the lowest price anywhere in the world is.That's what you're going to be paying. ...

Big Pharma is cutting investment in the UK as the government plays hardball with drugmakers over pricing, writes Matthew Brooker (via @opinion) https://t.co/yJo7zDj9qs ...

Indian firms are gearing up to supply the basic ingredient that goes in making copies of Novo's weight-loss drugs https://t.co/htCapzPlkP ...

British drugmaker GSK Plc pledged to invest $30 billion in the US over the next five years, making the announcement as President Donald Trump arrives in the UK for a highly anticipated state visit https://t.co/HkyI54iRBe ...

US regulators issued a flurry of letters calling out pharmaceutical companies for allegedly misleading ads https://t.co/nDUos3cssQ ...

The struggles of Novo Nordisk has economists wondering whether Denmark's economy relies too heavily on the success of the company -- and its blockbuster weight loss drugs https://t.co/oobJqrCUvI ...

Market Dynamics - Shares of Eli Lilly and Novo Nordisk experienced a decline [1] - US regulators established a "green list" of foreign manufacturers producing raw materials for GLP-1 drugs [1] Regulatory Landscape - The "green list" allows compounding pharmacies to create copies of blockbuster GLP-1 drugs [1]

Goldman Sachs and KKR are among lenders providing around €1.4 billion of one of the most expensive types of debt to back CapVest Partners’ acquisition of a majority stake in German drugmaker Stada Arzneimittel AG https://t.co/RXjEOE2v7s ...

Demand for Novo’s weight-loss blockbuster Wegovy is getting a boost in the UK from an unexpected corner: arch-rival Eli Lilly https://t.co/GLKpjCQVSC ...

Analyst Actions & Forecasts - Link Partners downgraded Eli Lilly (LLY) to market perform from outperform [1] - Link Partners lowered the price target for Eli Lilly from $944 to $715 [1] - Link Partners reduced 2030 orforglipron sales estimate from approximately $22 billion to $14 billion [3] - The analyst still expects orforglipron to be a mega-blockbuster drug [3] Competitive Landscape - Novo Nordisk is a wounded competitor in the obesity drug market duopoly and may resort to price competition [4][5] - Emerging competitors with novel therapies will increase market competition by the end of the decade [5] - Several companies are developing obesity assets in late-stage clinical development, including Amgen, AstraZeneca, Roche, Structure Therapeutics (GPCR), Viking Therapeutics, and Metacrine (META) [9] Market Access & Coverage - Employer coverage of anti-obesity medicines has not expanded significantly in the past 18 months and may not do so in the next 6 months [6] - Approximately 50 to 55 million commercial lives have coverage for anti-obesity medicines [7] - High-margin employers are more likely to offer coverage for these medications, while middle and low-margin employers may not have the financial resources due to the high prevalence of obesity [7]